 DUBLIN, Ireland, Oct. 28, 2020 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA, a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that it will report its third quarter and first nine months of 2020 financial results on Wednesday, November 4, after the close of the U.S. financial markets. 